Important note: Information in this article was accurate in June 2006. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 7, No. 6, June 2006
Simon Collins, HIV i-Base
A study by Mattias and colleagues from Gilead Sciences reported pharmacokinetic bioequivalence between the co-formulated fixed dose combination of efavirenz, tenofovir and FTC and plasma levels achieved when each drug was taken as single drug formulations.
48 HIV-negative volunteers were enrolled in a randomised cross-over study, using either test or reference formulations for one week, followed by a one week washout before switching formulations for a further week. Intensive PK was performed after each treatment.
Bioequivalence was assessed by 90% CI for the geometric least square means for Cmax AUC-t and AUC-infinity for each drug.
Comment
This is the first collaboration between two research-based pharmaceutical companies (Gilead and BMS) to produce a three-drug fixed-dose formulation. Although the project was announced by both companies in December 2004, several earlier attempts failed to produce bioequivalent results. This highlights the practical complexity of pharmacology, in an area than many people would expect to be routine and straight-forward.
Ref: Matthias A, Plummer A, Kearney B et al. Bioequivalence of the co-formulation of efavirenz/emtricitabine/tenofovir DF. 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006, Lisbon. Abstract 82.
2006-06-10
IB060706-17
©2006. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.